News Releases

Investor Alerts

Apr 21, 2020

Immunic, Inc. Reports that IMU-838, a Selective Oral DHODH Inhibitor, Has Demonstrated Preclinical Activity Against SARS-CoV-2 and Explores Plans for a Phase 2 Clinical Trial in COVID-19 Patients

- In Cellular Assays with SARS-CoV-2 Clinical Isolates, IMU-838 Shows Ability to Inhibit Viral Replication of SARS-CoV-2 -
Apr 17, 2020

Immunic, Inc. Announces Changes to Executive Team
Mar 16, 2020

Immunic, Inc. Reports Year End 2019 Financial Results and Highlights Recent Achievements

- Top-Line Data from Phase 2 EMPhASIS Trial in Relapsing-Remitting Multiple Sclerosis Expected in Third Quarter 2020 -
Feb 11, 2020

Immunic, Inc. to Participate in Scientific and Investor Conferences in February
Jan 8, 2020

Immunic Exercises its Option for the Exclusive Worldwide License to IMU-856 from Daiichi Sankyo Co., Ltd.

Phase 1 Clinical Studies to begin in First Half of 2020

Show per page

f